DAEJEON, South Korea, July 1, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced on July 1st that its subsidiary, Altos Biologics Inc. has submitted Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for an aflibercept biosimilar ALT-L9, developed by Alteogen.
Formycon`s Biologic Ahzantive (aflibercept-mrbb) Receives Approval in US
Alvotech and STADA add to strategic alliance through denosumab partnership
Enforcement Report - Week of June 5, 2024
Rezolute has posted midphase data on its oral eye disease drug candidate, sparking a share price jump as investors assessed its chances of rivaling Bayer and Regeneron’s injectable Eylea for the diabetic macular edema market.
BRIDGEWATER, N.J. and BENGALURU, India, May 21, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (US FDA) has approved the Company's first-to-file application for Yesafili™ (aflibercept-jbvf), an interchangeable* biosimilar aflibercept. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept).
The U.S. Food and Drug Administration (US FDA) has approved Biocon Biologics first-to-file application for Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA (aflibercept).
US FDA approves two biosimilars for blockbuster eye drug Eylea
Biocon Biologics’ Yesafili (aflibercept-jbvf) Receives Approval In U.S